Ohmium Announces CE Mark Approval for Lotus PEM Electrolyzers
Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures and deploys advanced Proton Exchange Membrane (PEM) electrolyzers, is proud to announce European CE mark approval for its Lotus 1.5 electrolyzer. The CE mark indicates that a product meets the European Union's stringent safety, health and environmental protection requirements. This achievement highlights Ohmium’s dedication to the highest quality and reliability standards and demonstrates its leadership in the green hydrogen industry.
Ohmium develops hydrogen generators, known as electrolyzers, that convert water into hydrogen and oxygen using electricity. When powered by renewable energy, these electrolyzers produce green hydrogen, a clean fuel that is positioned to play an important role in the transition to a sustainable energy future. Ohmium’s PEM electrolyzers feature integrated advanced power electronics that enable rapid dynamic ramping, essential for pairing with intermittent renewable energy. Delivering both high efficiency and high energy density, they are an ideal solution for green hydrogen production.
The CE mark indicates compliance with European safety directives and enables distribution across the European Economic Area (EEA). To achieve CE certification, the safety and quality compliance of Ohmium’s Lotus electrolyzer were thoroughly reviewed and documented. For this work, Ohmium applied ISO 22734 (“Hydrogen generators using water electrolysis: Industrial, commercial, and residential applications”) an international standard that provides manufacturers with a clear set of robust requirements. The process included a detailed evaluation of the product design, components, and testing procedures, along with an assessment of Ohmium’s quality control procedures. Bureau Veritas (BV), a recognized notified body, conducted a review of the pressure equipment with a focus on its design and testing.
“Unified safety standards facilitate the adoption of green hydrogen projects around the world,” explained Dr. Chock Karuppaiah, Ohmium CTO. “Ohmium is proud to apply our electrochemical, technical, and practical expertise to the development of these standards. We were among the leading industry stakeholders involved in the development and maintenance of ISO 22734, and also contributed to the development of the US and Canadian binational standard for the design of hydrogen electrolyzers, adopted in 2023.”
“Ohmium is committed to helping customers around the world transition to green hydrogen quickly, easily, and cost-effectively,” said Arne Ballantine, Ohmium CEO. “CE mark approval is an important milestone for quality and safety assurance, and also streamlines regulatory inspection and installation, making it even easier for our customers to achieve their goals.”
ABOUT OHMIUM
Ohmium designs, manufactures, and deploys modular, scalable Proton Exchange Membrane (PEM) electrolyzers that enable cost-competitive green hydrogen production. The company’s suite of electrochemical products helps customers achieve their sustainable energy goals across various industrial, transportation, and energy projects. Headquartered in the United States with manufacturing facilities in India and operations worldwide, Ohmium has a global green hydrogen project pipeline exceeding 2 GW across three continents. In 2023, Ohmium raised $250 Million in Series C financing, led by TPG Rise Climate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923300800/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest Integrates with Assembla to Streamline Bug Tracking for Development Teams3.6.2025 17:00:00 CEST | Press release
This Integration enables teams with seamless bug tracking capabilities directly from the testing environment, enhancing collaboration and accelerating software delivery cycles. LambdaTest, a unified agentic AI and cloud engineering platform, has announced its partnership with Assembla, a robust cloud-based platform for version control and project management. This collaboration enables software development teams to streamline their bug tracking processes and improve overall productivity. LambdaTest offers developers an exhaustive list of cloud-based testing solutions, including cross-browser compatibility testing, Web and App automation testing, and Real Device testing. Assembla users can now easily integrate with the LambdaTest platform to seamlessly mark bugs with detailed screenshots and assign them to team members. "This integration between LambdaTest and Assembla allows development teams to optimize their testing and bug tracking processes," said Mayank Bhola, Co-Founder and Head o
The Future of AI in the AEC Industry Unveiled at BST Global’s 2025 AI Summit3.6.2025 16:41:00 CEST | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, hosted its second annual AI Summit, May 6–8, 2025, in Palm Beach, FL. The premier event brought together 12 thought leaders from some of the world’s most influential firms, including Arcadis, Arup, AtkinsRéalis, Gensler, GHD, Jacobs, Mott MacDonald, NVIDIA, Parsons, Stantec, and WSP to share insights on how AI is reshaping the future of the AEC industry. Attendees as well as the broader AEC community praised the 2025 AI Summit for its timely content and line-up of industry trailblazers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603538561/en/ BST Global Chief Executive Officer Javier A. Baldor officially kicks off the AI Summit’s first full day of sessions by presenting his perspective on the driving forces impacting the AEC industry and the world at large. He shares three key ways AI and big data will transform nearly
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 20253.6.2025 16:30:00 CEST | Press release
Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET)Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the no
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD3.6.2025 16:12:00 CEST | Press release
- Approval Based on Positive Results from the Phase 3 HD21 Trial for StageIIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe - Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS’ Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma i
Automotive Industry Shifts Gears As Talent and Technology Take Center Stage3.6.2025 16:00:00 CEST | Press release
Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 130 leaders across automotive and tire manufacturers, original equipment manufacturers, engineering procurement companies and systems integrators across 15 countries, revealing a sector rapidly embracing change to stay competitive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603797393/en/ Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges. Workforce pressures have emerged as the most urgent challenge for automot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom